Clean Science and Technology Limited
Quality (79/100) does the heavy lifting; financial trend (8/100) is the drag.
Fair valueStocksWizard rates Clean Science and Technology Limited a Hold, scoring 46/100 on our blended model. On 36.5x trailing earnings it sits cheaper than the Chemicals median of about 41.0x. The price is about 41% below its 52-week high of ₹1,239.18 and 12% above the low of ₹656.4. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹1,002.07 implies about 36% upside across 14 analysts. It clears 7 of 13 investability checks, with durability 79, valuation 58 and momentum 9 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹656.81.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-40.50% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold46Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 15.3%
- Pass: Low debt (D/E < 0.5): 0.00x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -6%
- Fail: Earnings growing: -21%
- Pass: Net margin ≥ 10%: 24.0%
- Pass: Current ratio > 1.5: 5.01
- Pass: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 27.33
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter54.4%
- Institutions26.3%
- Public & other19.2%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (24.0%).
- Financially solid — Altman Z 27.33.
Opportunities
- Well off its 52-week high — possible mean-reversion.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Earnings contracting year on year.
About Clean Science and Technology Limited
Clean Science and Technology Limited manufactures fine and specialty chemicals across India, China, the Americas, Europe, and internationally. The company operates three segments: Performance Chemicals, FMCG Chemicals, and Pharmaceutical & Agro Intermediates, producing chemicals including monomethyl ether of hydroquinone, butylated hydroxy anisole, tertiary butyl hydroquinone, hindered amine light stabilisers, and butylated hydroxy compounds.
Clean Science and Technology Limited — frequently asked questions
Is Clean Science and Technology Limited a buy, hold or sell?
StocksWizard currently rates Clean Science and Technology Limited (CLEAN) a Hold, based on a blended score of 46/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Clean Science and Technology Limited's fair value?
Our blended DCF and relative-valuation model estimates Clean Science and Technology Limited's fair value at about ₹821.01, versus a current price of ₹737.3 — roughly 11% upside. On that basis the stock looks fairly valued.
Is Clean Science and Technology Limited financially healthy?
Clean Science and Technology Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Clean Science and Technology Limited's share price performed?
Clean Science and Technology Limited is down 10% over three months, and last traded at ₹737.3. Past performance doesn't predict future returns.
More in Chemicals
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.